Journal of Clinical Oncology
Articles in this Issue
Five-year follow-up of prostate specific membrane antigen PET/CT-guided salvage radiotherapy following radical prostatectomy: A single center retrospective analysis.
336 Background: Salvage radiation therapy (sRT) is standard of care for biochemically recurrent prostate cancer following radical prostatectomy (RP). In t...
Barriers to and facilitators of first-line treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC) by practice setting and intensification frequency: A sub-analysis of IMPLEMENT.
48 Background: First-line TI (i.e., androgen-deprivation therapy + chemotherapy, androgen receptor pathway inhibitors, or both) is recommended for mCSPC b...
LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.
392 Background: Prostate cancer (PCa) remains the second leading cause of cancer death in men. Neoadjuvant pharmacodynamic studies facilitate rational dec...
Association between post-orchiectomy systemic inflammatory indexes and tumor characteristics in clinical stage I germ cell tumours.
643 Background: Approximately 25-30% of clinical stage I (CSI) GCT patients will experience disease relapse after orchiectomy. Adding adjuvant treatment w...
Assessing racial disparities in testicular cancer survival: Evidence from a nationwide cohort.
621 Background: Testicular cancer is one of the most common and curable malignancies in young men, with a 5 year survival rate of 95%. Limited research ha...
EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial.
TPS880 Background: The standard treatment for patient with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant s...
Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.
719 Background: As the number of tx options for patients with la/mUC increases, physicians aiming to optimize tx choice and sequencing must make complex d...
Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
TPS432 Background: Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop BCR, defined...
Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).
669 Background: Fibroblast growth factor receptor (FGFR) inhibitor therapy improves overall survival in LA/mUC patients with FGFR 2/3 alterations and prio...
Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC).
161 Background: Patients (Pts) with mCRPC have a poor prognosis with limited treatment options, particularly those who have progressed after novel hormona...
Relationship between androgen deprivation therapy and kidney function in patients with prostate cancer: An analysis of the RADICAL-PC study.
115 Background: Androgen deprivation therapy (ADT) is an effective treatment for patients with advanced prostate cancer (PC). However, its impact on renal...
Natural history and risk-stratification of biochemical recurrence in prostate cancer treated with definitive radiotherapy.
348 Background: Biochemical recurrence (BCR) of prostate cancer following radiation therapy often does not result in clinically significant events, but a...
Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.
11 Background: Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited understanding of the tumor immune microenvironment (TIME). The inte...
Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.
657 Background: SHR-A2102 is a novel ADC that consists of a fully humanized IgG1 monoclonal antibody targeting nectin-4, a cleavable linker, and a topoiso...
Germline genetic variants in cancers of the urothelial tract and association with outcomes.
870 Background: Studies cite that 10-24% of patients (pts) with urothelial carcinoma (UC) have a pathogenic germline variant (var), but few have looked at...
PSMA-based PET imaging in newly diagnosed, high-risk localized prostate cancer, a National Cancer Institute (NCI) Cancer Moonshot trial.
327 Background: Prospective randomized trials have suggested that prostate specific membrane antigen (PSMA)-based PET/CT may improve the detection of meta...
Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).
461 Background: TIVO is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved in the US for treatment of pa...
Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC).
731 Background: EV+P received accelerated approval (AA) for cisplatin (cis)-ineligible aUC patients in April 2023 (EV-103) and full approval (FA) for all...
A phase II trial of dostarlimab and niraparib combination therapy in patients with stage III-IV recurrent or refractory penile cancer.
TPS14 Background: Penile squamous cell carcinoma (PSCC) is a rare and aggressive malignancy with limited therapeutic options, particularly for patients wh...
Functional and oncological outcome of primary nerve sparing retroperitoneal lymph node dissection in marker negative testicular germ cell tumors in clinical stage IIA/B.
641 Background: Guideline recommended treatment of choice for clinical stage IIA/B testicular nonseminomatous germ cell tumors (NSGCT) is the delivery of...
Spatial transcriptomic analysis of tumor tissue from patients with metastatic urothelial carcinoma (mUC) receiving ipilimumab (IPI) plus nivolumab (Nivo) combined with sacituzumab govitecan (SG).
863 Background: We previously reported that the combination of IPI-NIVO plus SG shows high efficacy with 83.3% objective response rate (ORR) and durable r...
Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan (SG)-treated patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC).
709 Background: In the rapidly evolving la/mUC treatment landscape, new therapies need to be integrated into management of pts. SG, a Trop-2–directed anti...
Evaluating disparities in prostate cancer-related mortality among diabetic adults in the United States and Texas: A 21-year observational study (1999-2020).
30 Background: The prostate cancer (PCa) mortality risk with diabetes is poorly understood and understudied. We aim to study the annual trends and sociode...
EMETPRO: A multicenter, international, retrospective analysis evaluating patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) with early progression (EP).
169 Background: Combination therapies, such as androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) +/- docetaxel, were shown t...
Impact of upstaging from cT2a–b to pT3a on overall survival (OS) among patients with renal cell carcinoma.
601 Background: Identifying patients with renal cell carcinoma (RCC) who may benefit from adjuvant systemic therapy has proven difficult. Approximately 40...